We reviewed our experience in 79 children who had unrelated cord blood transplant (UCBT) between 1996 and 2007 with a major focus on GVHD, comparing both traditional and National Institute of Health (NIH) criteria. The cumulative incidence (CI) of acute GVHD (aGVHD, by day þ 100) was 0.42 for grade II-IV and 0.22 for grade III-IV. The CI of all aGVHD (NIH, that is, no time limit) at 1 year was 0.45 for grade II-IV and 0.32 for grade III-IV. Infused CD34 cell dose (41 Â 10 5 /kg), pretransplant bacterial infection and nonmalignant disorders were risk factors for grade II-IV aGVHD on univariate analysis. Infused CD34 cell dose remained significant on multivariate analysis. At 1 year, the CI of chronic GVHD (cGVHD) using the Seattle criteria was 0.27, whereas that for cGVHD (NIH) was 0.08. By NIH criteria, the classic form of cGVHD was uncommon (5%) after UCBT. Instead, the acute (71%) and overlap (24%) GVHD variants predominated. Grade II-IV aGVHD was a significant risk factor for cGVHD by both Seattle and NIH criteria. We conclude that GVHD after day þ 100 after UCBT typically carries features of aGVHD. Moreover, and in marked contrast to adult unrelated donor hematopoietic stem cell transplantation, the GVHD observed in this series did not adversely affect survival.
Introduction
Unrelated cord blood transplant (UCBT) offers a readily available alternative source of stem cells for patients lacking matched related donors. 1 Its use has increased over the last decade in both pediatric and adult populations.
The incidence of GVHD after one or two Ag HLAmismatched UCBT is lower or comparable to that of HLAmatched unrelated transplants using adult donors. [2] [3] [4] One study comparing GVHD in children who received either cord blood or BM transplant from an HLA-identical sibling showed lower incidence of both acute GVHD (aGVHD) and chronic GVHD (cGVHD) after cord blood transplant. 5 The reported incidence of aGVHD (grade II-IV) in UCBT ranges between 14 and 52%. [1] [2] [3] [6] [7] [8] [9] [10] [11] [12] [13] Reported risk factors for aGVHD include CMV status before transplant, 8 infectious status after transplant, 1 patient age, 1 a high cryopreserved CD34 cell dose, 13 coexistence of class I and II HLA disparities 13 and degree of HLA mismatch. 14 The published incidence of cGVHD after UCBT ranges between 5 and 25%. [1] [2] [3] [6] [7] [8] [9] [10] [11] [12] [13] Risk factors for cGVHD include history of severe aGVHD, 1 low nucleated cell (NC) dose in malignant disease 14 and degree of HLA mismatch. 14 Until recently cGVHD was diagnosed and graded according to the classic or so-called Seattle criteria. 15 However, to better characterize cGVHD, the National Institute of Health (NIH) recently published new consensus criteria to diagnose and grade the severity of cGVHD. 16 The main theme of the new criteria is that the clinical signs of GVHD rather than the timing (that is, before or after 100 days following transplant) should be used as the basis for diagnosis of acute or chronic GVHD. Thus, patients with features of aGVHD after day 100 are diagnosed with late aGVHD rather than cGVHD, as previously carried out. The new NIH criteria have been increasingly used in recent clinical studies characterizing GVHD. [17] [18] [19] However, more studies with different hematopoietic stem cell sources are needed to assess whether the NIH criteria will be advantageous over traditional criteria to characterize cGVHD and predict treatment response and outcome after various forms of allogeneic stem cell transplant.
In this study, we reviewed our institutional experience from 1996 to 2007 using UCBT to treat malignant and nonmalignant disorders in children. This analysis focuses on characterization of acute and chronic GVHD, the risk factors for their occurrence and the influence of GVHD after UCBT on patient survival. We used both traditional and NIH criteria to diagnose and grade GVHD.
Patients and methods
Eligibility and donor selection A total of 81 consecutive patients were enrolled in our local institutional myeloablative UCBT protocol from January 1996 to July 2007. The study was approved by the institutional review board and all patients or their guardians signed informed consent forms before enrolling into the study. Two patients were excluded because of death before UCB infusion; thus, 79 patients were included in our analysis. All patients received a single cord blood unit for their transplant. Two patients failed first UCBT and underwent a second UCBT; each of these transplants was analyzed separately. Data were collected prospectively. The one exception in our analysis was that for the purposes of this study, a second grading of GVHD was carried out on the basis of a retrospective chart review using the new NIH guidelines. 16 HLA typing was performed using serological or lowresolution molecular methods for HLA-A and HLA-B, and high-resolution molecular typing for HLA-DRB1. Donors were selected on the basis of the degree of match and cryopreserved cell dose. Matching at HLA-DRB1 was prioritized. Infused NC dose was available in all patients and infused CD34 þ cell dose was available in all patients except one.
Conditioning regimens, GVHD prophylaxis and supportive care Conditioning regimens were myeloablative in all cases and varied depending on diagnosis, disease status at the time of transplant and, occasionally, on unique patient risk factors (Table 1) . Anti-T-cell serotherapy was given before UCBT in all cases, with 75 patients (95%) receiving antithymocyte globulin and 4 patients (5%) receiving alemtuzumab (Campath 1H). GVHD prophylaxis was mandated to be CsA and steroids and was accomplished as per protocol in 72 patients (91%). CsA was started on day À1 and trough levels of 150-250 ng/mL were targeted. In the absence of GVHD, CsA taper was initiated at day þ 100 (malignant disorders) or at day þ 180 (nonmalignant disorders) with the aim of completing the taper and discontinuing CsA over the subsequent 3 months if no GVHD developed. Methylprednisolone was started on day À5 at an initial dose of 5 mg/kg/day from day À5 to day À2, followed by 2 mg/kg/day from day À1 to day þ 1, which was then slowly tapered and discontinued by day þ 120 if there was no evidence of GVHD.
Supportive care was consistent throughout the cohort. All blood products were leukocyte-reduced and irradiated. Blood products were also CMV seronegative if the recipient was seronegative. All patients received G-CSF (10 mcg/kg/ day i.v.) from day þ 1 until their ANC reached 2.5 Â 10 9 /L. Thereafter, G-CSF was tapered and discontinued as tolerated to maintain an ANC 41 Â 10 9 /L. All patients received Pneumocystis carinii pneumonia prophylaxis, i.v. Ig, acyclovir prophylaxis, antibacterial prophylaxis (meropenem or imipenem) and antifungal prophylaxis (liposomal amphotericin B).
Infections in the peritransplant period
To study their influence on risk of GVHD, all culturedocumented infections were reviewed starting 3 months before transplant through the first 100 days after transplant. Infections were classified on the basis of the type of organism (bacterial, fungal or viral).
End points
The incidence and pattern of classic aGVHD grades II-IV and aGVHD grades III-IV (by day þ 100) were compared with those of aGVHD grades II-IV and aGVHD grades III-IV (NIH, that is, no time limit). Similarly, the incidence and clinical characteristics of GVHD after day þ 100, both classic cGVHD as defined by the Seattle criteria (Seattle) and cGVHD as defined by the NIH consensus criteria, were compared. Classic aGVHD was defined as aGVHD within the first 100 days after transplant. Acute GVHD (NIH) was defined as aGVHD occurring any time after transplant and was not limited to the first 100 days, that is, it included patients with aGVHD by day þ 100, in addition to patients with late-onset aGVHD based on NIH criteria. 16 Diagnosis and grading of aGVHD were performed according to standard criteria 20 for all patients with aGVHD by day þ 100 and for those patients with later-onset aGVHD were based on NIH criteria. Time of onset and pattern of organ involvement in aGVHD were determined by clinical signs, laboratory values and/or biopsy. The diagnosis of isolated gut GVHD was confirmed by biopsy in all patients. Patients with grade II-IV and III-IV aGVHD were analyzed separately for both classic aGVHD (by day þ 100) and aGVHD (NIH).
cGVHD was evaluable if patients survived longer than 100 days after transplant and had sustained donor engraftment. cGVHD (Seattle) was defined as patients who met the criteria for any GVHD after day þ 100 on the basis of Seattle classification.
15 cGVHD (NIH) was defined as patients who had classic clinical features of cGVHD based on NIH criteria, including patients with overlap syndrome and excluding patients with late-onset aGVHD without chronic features. 16 EFS was defined as the time from transplant to first event (failure of engraftment/graft rejection, relapse or death in CR) and OS was defined as the time from transplant to death from any cause.
Statistical analysis
The cutoff date for data analysis was 30 June 2007. Followup data were available in all patients. Cumulative incidence function was used to estimate the probability of classic aGVHD II-IV and classic aGVHD III-IV (by day þ 100), aGVHD II-IV (NIH), aGVHD III-IV (NIH), cGVHD (Seattle) and cGVHD (NIH). 21 Death, relapse or graft rejection/failure was considered as the competing risk.
Cumulative incidence values were calculated with the use of log transformation to ensure that they were between 0 and 1. Analyses of the effect of different variables on the risk of aGVHD and cGVHD were performed using Klein and Anderson's pseudo-values approach, which directly models the effect of covariates on the cumulative incidence (CI) function. [22] [23] [24] Analysis of the effect of aGVHD and cGVHD on EFS and OS was performed using the Kaplan-Meier method for univariate analysis.
All variables with a P-value p0.1 on univariate analysis were included in the multivariate analysis. Variables evaluated for influence on aGVHD and cGVHD included recipient CMV serology before transplant, CMV reactivation after transplant, blood type match, infused NC dose, infused CD34
þ cell dose, degree of HLA match, diagnosis, presence of infections (viral, fungal, bacterial or any) from day À90 to À1 and from day 0 to þ 100, TBI, age group (o11 years vs X11 years), gender, sex mismatch, ex vivo expansion of cord blood and presence of aGVHD II-IV or III-IV as applicable. P-value o0.05 was considered statistically significant. SAS 9.1 (SAS, Cary, NC, USA) was used for all analyses.
Results

Patient and transplant characteristics
Patient and transplant characteristics of the 79 evaluable patients are summarized in Table 1 . Ex vivo expanded cells from a portion of the cord blood unit were used in 20% of patients and the results of that study were previously reported. 25 aGVHD The CI of classic aGVHD (by day þ 100) was 0.42 (95% CI, 0.31-0.54) for grade II-IV and 0.22 (95% CI, 0.14-0.32) for grade III-IV. Table 2 summarizes the frequency of organ involvement in classic aGVHD on the basis of maximum grade. All patients with grade III or IV classic aGVHD had GI involvement and 33% of patients with grade III classic aGVHD had isolated GI involvement. Median day of onset of classic aGVHD was day þ 25 (range, day þ 10 to 93). Median day of onset of aGVHD based on organ involved was day þ 20 for liver, day þ 25 for skin and day þ 30 for GI.
Univariate analysis for potential variables that affect aGVHD II-IV or III-IV was performed for aGVHD using both the classic and NIH criteria. Variables that were associated with a statistically significant risk of classic aGVHD II-IV included a high infused CD34 þ cell dose (41 Â 10 5 /kg; P ¼ 0.04), presence of bacterial infection within 3 months before transplant (P ¼ 0.04) and non- Table 2 Organs involved by classic acute GVHD (by day +100) based on maximum grade (total patients ¼ 68) I  3  0  0  100%  II  16  6%  50%  87%  III  12  16%  100%  66%  IV  5  80%  100%  100% malignant disorders (P ¼ 0.04; Table 3 ). The high infused CD34 þ cell dose remained statistically significant (P ¼ 0.04) and bacterial infection within 3 months before transplant approached statistical significance (P ¼ 0.07) on multivariate analysis (Table 3) . None of the variables examined were associated with increased risk of classic aGVHD III-IV.
Statistical analyses were also performed for the risk of aGVHD II-IV or III-IV (NIH). The CI of aGVHD (NIH) at 1 year was 0.45 (95% CI, 0.34-0.57) for grade II-IV and 0.32 (95% CI, 0.22-0.43) for grade III-IV. Therefore, there is very little de novo grade II-IV aGVHD after day þ 100, although preexisting aGVHD may progress in severity, as evidenced by the increase in grade III-IV aGVHD after day þ 100. On univariate analysis, the presence of bacterial infection within 3 months before transplant (P ¼ 0.04) was the only statistically significant risk factor for aGVHD II-IV (NIH). High infused CD34 þ cell dose (41 Â 10 5 /kg; P ¼ 0.06) and nonmalignant disorders (P ¼ 0.08) approached statistical significance (Table 3) . On multivariate analysis, none of these variables reached significance; however, bacterial infection within 3 months before transplant and high infused CD34 þ cell dose approached significance ( Table 3 ). The cumulative risk of aGVHD III-IV (NIH) was significantly associated with the presence of any infection from day 0 to þ 100 (P ¼ 0.04; Table 3 ).
cGVHD
The CI of classic cGVHD (Seattle) at 1 year after transplant was 0.27 (95% CI, 0.18-0.37). New onset cGVHD was not noted after the first year following UCBT. On the basis of prospective assessment using the Seattle criteria, the type of cGVHD was limited in 2 (10%) and extensive in 19 (90%), and was de novo in 4 (19%), quiescent in 5 (24%) and progressive in 12 (57%).
Reclassification of GVHD after day þ 100 on the basis of NIH guidelines 16 is shown in Table 4 and the pattern of organs involved by cGVHD is shown in Table 5 . The majority of recipients of unrelated cord blood (71%) were reclassified as having aGVHD that was persistent, recurrent or late onset. The incidence of any of the features of cGVHD was 29% (six patients). Most of those patients (five of six) had the overlap syndrome with features of both acute and chronic GVHD, whereas isolated cGVHD features occurred in only one patient. The gut was the primary organ involved in overlap syndrome (Table 5) .
Global scoring of the severity of GVHD after day þ 100 on the basis of NIH guidelines was also performed. 16 At its peak grade, late GVHD was classified as severe in 52% of cases. For those patients with aGVHD (persistent, recurrent or late-onset), scoring was mild in five (33%), GVHD after unrelated cord blood transplant in children A Alsultan et al moderate in two (13%) and severe in eight (53%). Among patients with aGVHD subtypes, 66% had a maximal grade of III-IV aGVHD. Scoring was severe for the only patient with classic cGVHD. For those patients with overlap syndrome, scoring was mild in one (20%), moderate in two (40%) and severe in two (40%). Univariate analysis for potential variables that affect classic cGVHD (Seattle) was performed. The presence of classic aGVHD II-IV (P ¼ 0.002) was the only variable that was found to be a statistically significant risk factor. The CI of cGVHD (NIH) at 1 year after transplant was 0.08 (95% CI, 0.04-0.16). The presence of classic aGVHD II-IV was also a significant risk factor (P ¼ 0.02) for cGVHD (NIH). Negative recipient CMV serology before transplant (P ¼ 0.06) and low infused NC p3 Â 10 7 /kg (P ¼ 0.08) approached statistical significance as risk factors for cGVHD (NIH) ( Table 3 ). Multivariate analysis was not applicable because of the low number of patients with cGVHD (NIH; n ¼ 6).
Outcome
All 79 transplanted patients were evaluated for EFS and OS. Median follow-up duration was 5.09 years (range, 0.70-9.44 years). EFS and OS were 0.54 (95% CI, 0.43-0.65) and 0.68 (95% CI, 0.56-0.78) at 1 year, and 0.48 (95% CI, 0.36-0.54) and 0.60 (95% CI, 0.46-0.71) at 3 years, respectively. Overall relapse rate at 1 year after transplant was 0.15 (95% CI, 0.08-0.26) for all malignant disorders. All relapses occurred within the first year after transplant; median time to relapse was day þ 182 (range, days þ 29 to 306). TRM at day þ 100 was 0.18 (95% CI, 0.10-0.30).
There were no statistically significant effects of acute or chronic GVHD on EFS. The effects of classic aGVHD and aGVHD (NIH) on EFS were examined in all patients who successfully achieved neutrophil engraftment (n ¼ 68). Classic aGVHD did not alter 1-or 3-year EFS for either grade II-IV (P ¼ 0.87 at 1 year; P ¼ 0.83 at 3 years) or grade III-IV (P ¼ 0.53 at 1 year; P ¼ 0.50 at 3 years) disease (Figure 1) . Similarly, aGVHD (NIH) did not alter EFS for grade II-IV (P ¼ 0.90 at 1 year and P ¼ 0.69 at 3 years) or grades III-IV (P ¼ 0.53 at 1 year and P ¼ 0.76 at 3 years) disease.
A total of 25 patients had grade III-IV aGVHD (NIH). Of them, 13 (52%) are still alive, 2 (8%) relapsed and 10 (40%) died (causes were infections in 7, idiopathic pneumonia syndrome in 1, pulmonary hemorrhage in 1 and renal failure/infections in 1) with a median time to death of 212 days (range, 48-832 days). Among patients with malignant disorders, the CI of relapse at 1 year was 0.1 for those with grade III-IV aGVHD (NIH) compared with 0.15 for others with no statistically significant difference (P ¼ 0.3) between both groups.
The effects of cGVHD (Seattle) and cGVHD (NIH) on EFS were examined in patients who achieved donor engraftment and survived beyond day þ 100 (n ¼ 58). cGVHD (Seattle) did not alter EFS (P ¼ 0.12 at 1 year; P ¼ 0.85 at 3 years; Figure 2 ), nor did cGVHD (NIH; P ¼ 0.62 at 1 year; P ¼ 0.42 at 3 years). We also analyzed Table 5 Organs involved by GVHD after day +100 based on NIH criteria
Acute (persistent, recurrent, late-onset; n ¼ 15)
Abbreviation: MS ¼ musculoskeletal. a Lung biopsy on day +180 showed lymphocytic bronchitis consistent with early GVHD and was not conclusive for bronchiolitis obliterans. the effects of acute and chronic GVHD using both criteria on nonrelapse mortality and none of them were found to significantly affect 1-or 3-year EFS (data not shown).
Discussion
In this study, we reviewed our institutional experience with UCBT with specific focus on GVHD. The incidence of classic grade III-IV aGVHD in our patient population was 0.22, which is within the range of the reported incidence of aGVHD in other series of UCBT. [1] [2] [3] [6] [7] [8] [9] [10] [11] [12] [13] 26 An infused CD34 þ cell dose 41 Â 10 5 /kg was associated with increased risk of grade II-IV aGVHD, similar to the observation of Gluckman et al., 13 who reported an association of the CD34 þ cell dose at freezing with increased risk of aGVHD. On the other hand, a high NC dose was not associated with an increased incidence of aGVHD. This suggests that CD34 þ cells either directly possess or are associated with unique biological features predisposing to aGVHD.
Bacterial infection within 3 months before transplant approached statistical significance as a risk factor for grade II-IV aGVHD. This may be in part related to the fact that effective antibacterial therapy allows prompt clinical responses and shorter delays in proceeding to transplant compared with either viral or fungal infections. Thus, the systemic inflammatory milieu triggered by bacterial infection may persist into the transplant period and add to the post transplant cytokine storm and subsequent risk of aGVHD. 27 There was no difference in our analysis for potential risk factors for grade II-IV aGVHD between classic aGVHD or aGVHD (NIH). However, it seems that any infection within 100 days of transplant was a risk factor for grade III-IV aGVHD (NIH), but not for classic grade III-IV aGVHD. This may again be related to early infections after transplant, resulting in a systemic inflammatory milieu that increases the risk of severe aGVHD even after day þ 100.
The risk of GVHD in our patient population was not associated with the degree of HLA match. The cord blood matching strategy used in our study specifically prioritizing HLA-DRB1 matching may have affected our reported experience and comparisons with reports from other centers, wherein different matching strategies may be used. As the experience and number of UCBT increases, the impact of more subtle aspects of class I and class II mismatching on the frequency, character and outcome of GVHD may emerge.
Isolated GI aGVHD was observed in about one-third of patients with grade III aGVHD (by day þ 100), reinforcing the importance of considering GVHD and using endoscopic biopsy to reach a diagnosis when symptoms are limited to this single-organ system. 20 Isolated liver aGVHD, on the other hand, was not observed in our patient population.
Reclassification of GVHD after day þ 100 based on NIH criteria 16 showed that late GVHD (which would have been classified as cGVHD using the Seattle criteria) after UCBT seems to present most often as flares of aGVHD, with 71% of our patients with GVHD after day þ 100 having persistent, recurrent or late-onset aGVHD findings. cGVHD features only occurred in 29% of cases (24% overlap and 5% only classic cGVHD). These findings are different compared with cGVHD after matched unrelated PBSC transplant or BMT in which classic features of cGVHD are relatively common. 15, 28, 29 One retrospective study reclassified cGVHD on the basis of NIH guidelines for matched related-donor transplants and found that 85% of those with late GHVD (after day þ 100) had classic cGVHD features (28% overlap and 57% only classic cGVHD), whereas only 15% had only aGVHD features. 19 A similar proportion of classic cGVHD (79%; 30% overlap and 49% only classic cGVHD) was observed in another retrospective study that included both related and unrelated BM and PBSC transplants. 18 However, there have been no published studies that directly evaluate cGVHD after UCBT or compare cGVHD incidence and features between UCBT and unrelated donor PBSC transplant or BMT on the basis of NIH criteria.
The difference between 'acute' vs 'classic' subtypes of late GVHD may result from biologically different T-cell subsets. Both experimental and clinical allogeneic data show aGVHD to be associated with a T helper1 cytokine profile, whereas cGVHD is associated with T cells with a T helper2 cytokine profile. 30, 31 It is yet to be determined whether cytokine profiles of T cells correlate with the late GVHD subtype as defined by the NIH consensus guidelines. Such potential differences in T-cell biology could explain the better response rate to GVHD treatment observed in UCBT compared with unrelated adult donor hematopoietic stem cell transplantation 32 and may guide future anti-GVHD therapy development. Finally, T-cell priming to disparate HLA determinants, required in UCBT, but not in unrelated adult donor PBSC transplant or BMT, may be a factor in the observed tendency to detect late-onset aGVHD after UCBT.
In this study, the presence of classic grade II-IV aGVHD was the only significant predictor for cGVHD (Seattle), which is similar to the findings of Rubinstein et al.
1 Grade II-IV classic aGVHD was also a significant risk factor for cGVHD (NIH) consistent with observations that aGVHD is a specific predisposing factor for classic cGVHD. Negative recipient CMV serology before transplant and low infused NC dose approached statistical significance as risk factors for cGVHD (NIH). Gluckman et al.
14 showed that low NC dose was associated with higher cGVHD after UCBT in malignant disorders. This may be related to improved generation of regulatory T cells associated with higher NC dose.
The most striking finding of our study was that the presence and severity of acute and chronic GVHD (using both Seattle and NIH classifications) had no significant influence on EFS in our patients receiving UCBT. This contrasts with the adverse survival impact of severe forms of acute and chronic GVHD in matched unrelated donor hematopoietic stem cell transplantation or matched family member hematopoietic stem cell transplantation. One explanation is that GVHD was sufficiently manageable so as to not affect survival. Our finding is also supported by a recent study by MacMillan et al. 33 that showed increased aGVHD II-IV after double UCBT; however, this had no impact on TRM.
Our study is aided by being a single institutional experience with a consistent protocol for patient care and prospective data collection. On the other hand, our findings may be less generalizable, as they represent a single institution experience and a relatively small number of patients. However, despite these limitations, our findings provide preliminary evidence that classic cGVHD is relatively uncommon after UCBT. Instead, GVHD after day þ 100 in UCBT is predominantly aGVHD, when classified by the NIH criteria. Understanding the unique biology of T cells in GVHD after UCBT may direct new therapeutic interventions and these may differ from treatments being developed for cGVHD after PBSC transplant or BMT. We believe that the recently published NIH guidelines for diagnosing and classifying cGVHD may provide a better way of characterizing cGVHD, which could help in further understanding its biology. Future studies with a larger number of patients are warranted to further characterize GVHD after UCBT and to evaluate its impact on survival.
